Keros Therapeutics Announces Preliminary Results of Tender Offer
(NasdaqGM:KROS), LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price […]